Table 2.
Registered clinical trials based on matricellular proteins as biomarkers
| Family | Model | Trial Design | Status | Trial Number |
|---|---|---|---|---|
| Thrombospondins (TSPs) | Intracerebral Hemorrhage | Determine the predictive effect of TSP1 levels (plasma) in patients with acute intracerebral hemorrhage | Completed | NCT02465671 |
| Diabetes | Expression of TSP1 (blood and vitreous) in diabetes | Completed | NCT01809093 | |
|
| ||||
| Osteopontin | Coronary Artery Disease (CAD) | OPN and other proteins as biomarkers (plasma) for CAD severity | Completed | NCT02159235 |
|
| ||||
| (OPN) | Osteoarthritis | Expression of OPN and other proteins (synovial fluid) in osteoarthritis and correlation to inflammatory markers | Recruiting | NCT01993342 |
| Head, Neck, Lung Cancers | OPN and other proteins as biomarkers (serum, tumor) for head, neck, and lung cancers | Recruiting | NCT00568490 | |
| Mesothelioma | OPN and other proteins as biomarkers (serum) for malignant pleural mesothelioma | Completed | NCT02029105 | |
|
| ||||
| CCN | Transitional Cell Carcinoma | Expression of CCN1/CYR61 in urinary tract transitional cell carcinomas | Pending | NCT01189838 |
| Non-small Cell Lung Cancer | CCN1/CYR61 as a transcript biomarker (salivary) for non-small cell lung cancer detection | Recruiting | NCT02294578 | |
| Proliferative Retinopathy | CCN1/CYR61 as a biomarker (vitreous) for different stages of proliferative diabetic retinopathy | Completed | NCT01920984 | |
| Atrial Fibrillation | CTGF as a biomarker (plasma) for recurrence of atrial fibrillation after surgical maze procedure | Completed | NCT00542659 | |
| Kidney Disease | CTGF as a biomarker (urinary and serum) for chronic allograft nephropathy | Completed | NCT00056784 | |
|
| ||||
| SPARC | Triple Negative Metastatic Breast Cancer | SPARC expression in breast tumors as a prediction for progression-free survival post chemotherapy | Completed | NCT00479674 |
| Non-Small Cell Lung Cancer | SPARC expression and correlation with overall survival post chemotherapy | Completed | NCT00540514 | |
| Periostin | Chronic Kidney Disease | Periostin as a biomarker (urinary) for renal pathology and chronic kidney disease | Completed | NCT02493101 |
| Bone Fragility | Periostin as a biomarker (serum) for cortical porosity in hyperparathyroidism patients | Recruiting | NCT02524041 | |
| Asthma | Periostin as a biomarker (serum) for “allergic” vs. “non-allergic” asthma | Completed | NCT01618318 | |
| Periodontal Disease | Periostin as a biomarker (gingival crevicular fluid (GCF), saliva, serum) for susceptibility and/or progression of periodontal disease | Completed | NCT01180920 | |
|
| ||||
| Autotaxin | Intrahepatic cholestasis of pregnancy | Determine the diagnostic accuracy of autotaxin as a biomarker for cholestasis and differentiate ICP from of liver disorders | Recruiting | NCT02480478 |
|
| ||||
| PEDF | Diabetes mellitus | Measure levels and isoforms of PEDF and TSP-1 to determine correlation with diabetic retinopathy severity | Completed | NCT01809093 |
Selected clinical trials from the U.S. National Institutes of Health database, ClinicalTrials.gov